阿德福韦酯治疗慢性乙肝临床分析

Clinical analysis of adefovir dipivoxil in the treatment of chronic hepatitis B

目的对阿德福韦酯治疗慢性乙肝的临床效果进行分析。方法选取2011年6月~2014年9月在我院接受治疗的112例慢性乙肝患者,按照数字随机表法分为对照组和观察组各56例。本次治疗共分为两个阶段,第一阶段为12周,第二阶段为36周,对照组第一阶段服用安慰剂进行治疗了,第二阶段服用阿德福韦酯进行治疗;观察组一直使用阿德福韦酯进行治疗。比较两组患者第一阶段末和第二阶段末的治疗效果。结果第一阶段末,两组患者血清HBV-DNA与基线水平比较均存在明显差异（P〈0.05）,且观察组HBV-DNA水平明显低于对照组（P〈0.05）;第二阶段末,两组患者血清HBV-DNA水平均得到显著降低（P〈0.05）;比较两组患者中血清HBV-DNA≥2log10的患者,与基线数值比较无明显差异（P〉0.05）。结论采用阿德福韦酯治疗慢性乙肝,治疗效果显著,安全性高,值得推广应用。

Objective To analyze the clinical effect of adefovir dipivoxil in the treatment of chronic hepatitis B. Methods 112 cases of patients with chronic hepatitis B treated in our hospital from June 2011 to September 2014 were selected and divided into the control group and the observation group according to the digital random table with 56 cases in each. The treatment was divided into two phases, the first phase was 12 weeks, and the second stage was 36 weeks. Patients in the control group in first stage were treated with placebo, and patients in the second phase were treated with adefovir dipivoxil. Patients in the observation group were treated with adefovir dipivoxil all along. The effects between the two groups were compared at the end of the first stage and the end of the second stage. ResultsAt the end of the first stage, the serum HBV-DNA and baseline comparison of two groups were significantly different（P〈0.05）, and the level of HBV-DNA of the observation group was significantly lower than that of the control group（P〈0.05）. At the end of the second stage, serum HBV-DNA levels of the two groups were decreased significantly（P〈0.05）. The patients were compared between the two groups, whose serum HBV-DNA were more than or equal to 2log10, and there was no significant difference in baseline values（P〉0.05）. Conclusion Using the adefovir dipivoxil to treat chronic hepatitis B, the effect is significant, the security is high, and it is worth popularizing and applying.